Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs

Journal of Pharmaceutical Sciences

Volumn 105, Issue 9, 2016, Pages 2527-2544

  Baghel, Shrawan ^a   Cathcart, Helen ^a   O'Reilly, Niall J ^a  

^a Ireland   (Ireland)

Author keywords

Biopharmaceutics Classification System; crystallization; dissolution; drug excipient interaction; formulation; in silico modeling; oral drug delivery; polymeric drug delivery systems; solid dispersion; supersaturation

Indexed keywords

AMORPHOUS DRUG; DRUG; DRUG CARRIER; POLYMER; SOLVENT; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; CRYSTALLIZATION; DISPERSION; DRUG CLASSIFICATION; DRUG SOLUBILITY; DRUG STABILITY; ENTHALPY; FLORY HUGGINS THEORY; GLASS TRANSITION TEMPERATURE; HYDROPHILICITY; MELTING POINT; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; PHASE TRANSITION; PHYSICAL CHEMISTRY; PLASTICITY; POLYMERIC AMORPHOUS SOLID DISPERSION; POLYMERIZATION; PREFORMULATION; REVIEW; SOLID STATE; SPECTROSCOPY; THEORY; THERMAL ANALYSIS; THERMODYNAMICS; WATER VAPOR; X RAY POWDER DIFFRACTION; CHEMISTRY; CLASSIFICATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

BIOPHARMACEUTICS; CRYSTALLIZATION; DRUG CARRIERS; DRUG STABILITY; PHARMACEUTICAL PREPARATIONS; POLYMERS; SOLUBILITY;

EID: 84982072403     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2015.10.008     Document Type: Review

References (217)

1. 1 Aulton, M., Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 3rd ed., 2008, Churchill Livingstone Elsevier, London, 441–482.
2. 2 Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavaliability. Pharm Res 12 (1995), 413–420.
3. 3 Yasir, M., Asif, M., Kumar, A., Aggarval, A., Biopharmaceutical classification: an account. Int J Pharm Tech Res 2 (2010), 1681–1690.
4. 4 Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000, USFDA, CDER.
5. 5 Childs, S., Kandi, P., Lingireddy, S., Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol Pharm 10 (2013), 3112–3127.
6. 6 Tripathi, K., Essentials of Medical Pharmacology. 6th ed., 2006, Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, 293.
7. 7 Jain, S., Patel, N., Lin, S., Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Dev Ind Pharm 41 (2015), 875–887.
8. 8 Douroumis, D., Fahr, A., Drug Delivery Strategies for Poorly Water Soluble Drugs. Advances in Pharmaceutical Technology. 2013, Wiley Publication, UK.
9. 9 William, R., Watts, A., Miller, D., Formulating Poorly Water Soluble Drugs. AAPS Advances in Pharmaceutical Science Series III. 2012, Springer Publication, NY.
10. 10 Roggy, M., Taft, D., Preclinical Drug Development. 2010, Informa Healthcare, Taylor and Francis Group. CRC Press, 2nd edition. NY.
11. 11 Mooter, G., The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. Drug Discov Today Technol 9 (2012), e79–e85.
12. 12 Zhang, M., Li, H., Lang, B., et al. Formulation and delivery of improved amorphous fenofibrate solid dispersion prepared by thin film freezing. Eur J Pharm Biopharm 82 (2012), 534–544.
13. 13 Eloy, J., Marchetti, J., Solid dispersions containing ursolic acid in poloxamer 407 and PEG 6000: A comparative study of fusion and solvent methods. Powder Technol 253 (2014), 98–106.
14. 14 Vo, C., Park, C., Lee, B., Current trend and future perspective of solid dispersions containing poorly water soluble drugs. Eur J Pharm Biopharm 85 (2013), 799–813.
15. 15 Huang, Y., Dai, W., Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B 4 (2014), 18–25.
16. 16 Teja, S., Patil, S., Shete, G., Patel, S., Bansal, A., Drug-excipient behaviour in polymeric amorphous solid dispersions. J Excip Food Chem 4 (2013), 70–94.
17. 17 Kumavat, S., Chaudhari, Y., Badhe, M., Borole, P., Physical stability of amorphous solid dispersion: a review. Int J Pharm Arch 2 (2013), 129–136.
18. 18 William, H., Trevaski, N., Charman, S., Shanker, R., Pouton, C., Strategies to address low drug solubility in discovery and development. Pharmacol Rev 65 (2013), 315–499.
19. 19 Brough, C., William, R. 3rd, Amorphous solid dispersion and nano crystal technologies for poorly water-soluble drug delivery. Int J Pharm 453 (2013), 233–252.
20. 20 Kawakami, K., Pikal, M., Calorimetric investigation of the structural relaxation of amorphous materials: evaluating validity of the methodologies. J Pharm Sci 94 (2005), 948–965.
21. 21 Graeser, K., Patterson, J., Zeitler, J., Rades, T., The role of configurational entropy in amorphous systems. Pharmaceutics 2 (2010), 224–244.
22. 22 Roos, H., Water Activity and Glass Transition. Water Activity in Foods. 1st ed., 2007, Blackwell Publishing and IFT Press, Oxford, 29–46.
23. 23 Crowley, K., Zografi, G., The use of thermal methods for predicting glass-former fragility. Thermochim Acta 380 (2001), 79–93.
24. 24 Stillinger, F., Supercooled liquids, glass transition, and the kauzmann paradox. J Chem Phys 88 (1988), 7818–7825.
25. 25 Hancock, C., Parks, M., What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res 17 (2000), 397–404.
26. 26 Sousa, L., Reutzel-Edens, S., Stephenson, G., Taylor, L., Assessment of the amorphous “solubility” of a group of diverse drugs using new experimental and theoretical approaches. Mol Pharm 12 (2015), 484–495.
27. 27 Babu, N., Nangia, A., Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des 11 (2011), 2662–2679.
28. 28 Yu, H., Hadinoto, K., Mitigating the adverse effect of spray drying on the supersaturation generation capability of amorphous nanopharmaceutical powders. Powder Technol 277 (2015), 97–104.
29. 29 Brouwers, J., Brewster, M., Augustijns, P., Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability?. J Pharm Sci 98 (2009), 2549–2572.
30. 30 Sun, D., Lee, P., Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation. Mol Pharm 10 (2013), 4330–4346.
31. 31 Kadajji, V., Betageri, G., Water soluble polymers for pharmaceutical applications. Polymers 3 (2011), 1972–2009.
32. 32 Donnelly, C., Tian, Y., Potter, C., Jones, D., Andrews, G., Probing the effects of experimental conditions on the character of drug polymer phase diagrams constructed using Flory-Huggins theory. Pharm Res 32 (2015), 167–179.
33. 33 Cui, Y., Amaterial science perspective of pharmaceutical solids. Int J Pharm 339 (2007), 3–18.
34. 34 Kawakami, K., Theory and practice of supersaturable formulations for poorly soluble drugs. Ther Deliv 6 (2015), 339–352.
35. 35 Zhao, M., Barker, S., Belton, P., McGregor, C., Craig, D., Development of fully amorphous dispersions of a low Tg drug via co-spray drying with hydrophilic polymers. Eur J Pharm Biopharm 82 (2012), 572–579.
36. 36 Li, S., Liu, Y., Liu, T., Zhao, L., Feng, N., Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm 411 (2011), 172–177.
37. 37 Knopp, M.M., Olesen, N.E., Holm, P., Langguth, P., Holm, R., Rades, T., Influence of polymer molecular weight on drug-polymer solubility: a comparison between experimentally determined solubility in PVP and prediction derived from solubility in monomer. J Pharm Sci 104:9 (2015), 2905–2912.
38. 38 Wu, J., Yang, M., Berg, F., Pajander, J., Rades, T., Rantanen, J., Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. Eur J Pharm Sci 44 (2011), 610–620.
39. 39 Paudel, A., Mooter, G., Influence of solvent composition on the miscibility and physical stability of Naproxen/PVP K25 solid dispersion preparation by cosolvent spray drying. Pharm Res 29 (2011), 251–270.
40. 40 Jahangiri, A., Jalali, M., Garjani, A., et al. Physicochemical characterization and pharmacological evaluation of ezetimibe-PVP K30 solid dispersions in hyperlipidemic rats. Colloids Surf B Biointerfaces 134 (2015), 423–430.
41. 41 Knopp, M., Olesen, N., Holm, P., Langguth, P., Holm, R., Rades, T., Influence of polymer molecular weight on drug-polymer solubility: a comparison between experimentally determined solubility in PVP and prediction from solubility in monomer. J Pharm Sci 104 (2015), 2905–2912.
42. 42 Mahmah, O., Tabbakh, R., Kelly, A., Paradkar, A., A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine. J Pharm Pharmacol 66 (2013), 275–284.
43. 43 Marasani, N., Tran, T., Poudal, B., et al. Fabrication and evaluation of pH-modulated solid dispersion for Telmisartan by spray-drying technique. Int J Pharm 441 (2013), 424–432.
44. 44 Kannaujia, P., Lau, G., Hg, W., et al. Nanoparticle formation and growth during in vitro dissolution of ketoconazole solid dispersion. J Pharm Sci 100 (2011), 2876–2885.
45. 45 Nagy, Z., Balogh, A., Demuth, B., et al. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole. Int J Pharm 480 (2015), 137–142.
46. 46 Shibata, Y., Fujii, M., Suzuki, A., et al. Effect of storage conditions on the recrystallization of drugs in solid dispersions with crospovidone. Pharm Dev Technol 19 (2014), 468–474.
47. 47 Mahmoudi, Z., Upadhye, S., Ferrizzi, D., Siahboomi, A., In vitro characterization of a novel polymeric system for preparation of amorphous solid drug dispersions. AAPS J 16 (2014), 685–697.
48. 48 Wu, J., Ho, H., Chen, Y., Chen, C., Sheu, M., Thermal analysis and dissolution characteristics of nifedipine solid dispersions. J Food Drug Anal 20 (2012), 27–33.
49. 49 Seo, S., Han, H., Chun, M., Choi, H., Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol HS15 as a carrier. Int J Pharm 424 (2012), 18–25.
50. 50 Medarevic, D.P., Kachrimanis, K., Mitric, M., Djuris, J., Djuric, Z., Ibric, S., Dissolution rate enhancement and physicochemical characterization of carbamazepine-poloxamer solid dispersions. Pharm Dev Technol, 2015 Jan 13 [Epub ahead of print].
51. 51 Medarevic, D., Kachrimanis, K., Mitric, M., Djuris, J., Djuric, Z., Ibric, S., Dissolution rate enhancement and physicochemical characterization of carbamazepine-poloxamer solid dispersions. Pharm Dev Technol 13 (2015), 1–9.
52. 52 Liu, X., Lu, M., Guo, Z., Huang, L., Feng, X., Wu, C., Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res 29 (2011), 806–817.
53. 53 Zidan, A., Rahman, Z., Sayeed, V., Raw, A., Yu, L., Khan, M., Crystallinity evaluation of tacrolimus solid dispersion by chemometric analysis. Int J Pharm 423 (2012), 341–350.
54. 54 Skotniki, M., Gawel, A., Cebe, P., Pyda, M., Thermal behaviour and phase identification of Valsartan by standard and temperature modulated differential scanning calorimetry. Drug Dev Ind Pharm 39 (2013), 1508–1514.
55. 55 Yan, Y., Sung, J., Kim, K., et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int J Pharm 422 (2012), 202–210.
56. 56 Sarode, A., Sandhu, H., Shah, N., Malick, W., Zia, H., Hot melt extrusion (HME) for amorphous solid dispersions: predictive tools for processing and impact of drug-polymer interactions on supersaturations. Eur J Pharm Sci 48 (2013), 371–384.
57. 57 Li, B., Konecke, S., Harich, K., Wegiel, L., Taylor, L., Edgar, K., Solid dispersion of quercetin in cellulose derivative matrices influences both solubility and stability. Carbohydr Polym 92 (2013), 2033–2040.
58. 58 Parikh, T., Gupta, S., Meena, A., Vitez, I., Mahajan, N., Serajuddin, A., Application of film-casting technique to investigate drug-polymer miscibility in solid dispersion and hot-melt extrudates. J Pharm Sci 104 (2015), 2142–2152.
59. 59 Ghosh, I., Snyder, J., Vippagunta, R., et al. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Int J Pharm 419 (2011), 12–19.
60. 60 Soti, P., Bocz, K., Pataki, H., et al. Comparison of spray drying, electroblowing and electrospinning for preparation of Eudragit E and itraconazole solid dipsersions. Int J Pharm 494 (2015), 23–30.
61. 61 Kim, N., Choi, D., Lim, J., et al. Investigation of polymeric excipients for dutasteride solid dispersion and its physicochemical characterization. Arch Pharm Res 37 (2014), 214–224.
62. 62 Beak, I., Kim, M., Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem Pharm Bull 60 (2012), 1468–1473.
63. 63 Kojima, T., Higashi, K., Suzuki, T., Tomono, K., Moribe, K., Yamamoto, K., Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with Eudragit E. Pharm Res 29 (2012), 2777–2791.
64. 64 Sun, D., Lee, P., Probing the mechanism of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers. J Control Release 211 (2015), 85–93.
65. 65 Lepek, P., Sawiki, W., Wlodarski, K., Wojnarowska, Z., Paluch, M., Guzik, L., Effect of amorphization method on Telmisartan solubility and the tableting process. Eur J Pharm Biopharm 83 (2013), 114–121.
66. 66 Zhong, L., Zhu, X., Luo, X., Su, W., Dissolution properties and physical characterization of Telmisartan-Chitosan solid dispersions prepared by mechanomechanical activation. AAPS PharmSciTech 14 (2013), 541–550.
67. 67 Wlodarski, K., Haber, K., Sawiki, W., et al. Physicochemical properties of tadalafil solid dispersions—impact of polymer on the apparent solubility and dissolution rate of tadalafil. Eur J Pharm Biopharm 94 (2015), 106–115.
68. 68 Alshahrani, S., Lu, W., Park, J., et al. Stability enhanced hot-melt extruded amorphous solid disperisons via combinations of soluplus and HPMC-HF. AAPS PharmSciTech 16 (2015), 824–834.
69. 69 Potter, C., Tian, Y., Walker, G., et al. Novel supercritical carbon dioxide impregnation technique for the production of amorphous solid drug dispersions: a comparison to hot melt extrusion. Mol Pharm 12 (2015), 1377–1390.
70. 70 Zhang, M., Li, H., Lang, B., et al. Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing. Eur J Pharm Biopharm 82 (2012), 534–544.
71. 71 Shamma, R., Basha, M., Soluplus: a novel polymeric solubilizer for optimization of Carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol 237 (2013), 406–414.
72. 72 Vasa, D., Dalal, N., Katz, J., et al. Physical characterization of drug:polymer dispersion behaviour in polyethylene glycol 4000 solid dispersions using a suite of complementary analytical techniques. J Pharm Sci 103 (2014), 2911–2923.
73. 73 Hirasawa, N., Ishise, S., Miyata, H., Danjo, K., Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers. Chem Pharm Bull 52 (2004), 244–247.
74. 74 Alhalaweh, A., Alzghoul, A., Mahlin, D., Bergstrom, C., Physical stability of drugs after storage above and below the glass transition temperature: relationship to glass forming ability. Int J Pharm 495 (2015), 312–317.
75. 75 Mahlin, D., Bergstrom, C., Early drug development predictions of glass-forming ability and physical stability of drugs. Eur J Pharm Sci 49 (2013), 323–332.
76. 76 Patterson, J., James, M., Forster, A., Lancaster, R., Butler, J., Rades, T., The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J Pharm Sci 94 (2005), 1998–2012.
77. 77 Li, j, Zhao, J., Wang, J., et al. The effect of polymeric excipients on the physical properties and performance of amorphous solid dispersions: part I, free volume and glass transition. Pharm Res 32 (2015), 500–515.
78. 78 Nunes, T., Viciosa, M., Correia, N., Nunes, R., Diogo, H., A stable amorphous statin: solid-state NMR and dielectric studies on dynamic heterogeneity of simvastatin. Mol Pharm 11 (2014), 727–737.
79. 79 Graeser, K., Patterson, J., Zeitler, J., Gordon, K., Rades, T., Correlating thermodynamic and kinetic parameter with amorphous stability. Eur J Pharm Sci 37 (2009), 492–498.
80. 80 Nanakwami, K., Modi, S., Kumar, L., Bansal, A., Role of thermodynamic, kinetic and structural factors in the recrystallization behaviour of amorphous erythromycin salts. Thermochimica Acta 582 (2014), 77–85.
81. 81 Marsac, P., Konno, H., Taylor, L., A comparison of the physical stability of amorphous felodipine and nifedipine. Pharm Res 23 (2006), 2306–2316.
82. 82 Guo, Z., Li, M., Pang, H., Lin, L., Liu, X., Wu, C., The utilization of drug-polymer interactions for improving the chemical stability of hot-melt extruded solid dispersions. J Pharm Pharmacol 66 (2014), 285–296.
83. 83 Sarode, A., Sandhu, H., Shah, N., Malick, W., Zia, H., Hot melt extrusion for amorphous solid disperisons: temperature and moisture activated drug-polymer interactions for enhanced stability. Mol Pharm 10 (2013), 3665–3675.
84. 84 Branham, M., Moyo, T., Govender, T., Preparation and solid state characterization of ball milled saquinavir mesylate for solubility enhancement. Eur J Pharm Biopharm 80 (2012), 194–202.
85. 85 Keratichewanun, S., Yoshihashi, Y., Sutanthavibul, N., Terada, K., Chatchawalsaisin, J., An investigation of nifedipine miscibility in solid dispersions using Raman spectroscopy. Pharm Res 32 (2015), 2458–2473.
86. 86 Joe, J.H., Lee, W.M., Park, Y.J., et al. Effect of solid-dispersions method on the solubility and crystalline property of tacrolimus. Int J Pharm 395 (2010), 161–166.
87. 87 Homayouni, A., Sadeghi, F., Nokhodchi, A., Varhosaz, J., Garekani, H., Preparation and characterization of celecoxib dispersions in soluplus: comparison of spray drying and conventional methods. Iran J Pharm Res 14 (2015), 35–50.
88. 88 Nielsen, L., Keller, S., Boisen, A., Mullertz, A., Rdes, T., A slow cooling rate of indomethacin in microcontainers increases the physical stability of the amorphous drug without influencing its biorelevant dissolution behaviour. Drug Deliv Transl Res 4 (2014), 268–274.
89. 89 Paudal, A., Loyson, Y., Mooter, G., An investigation into the effect of spray drying temperature and atomizing conditions on miscibility, physical stability and performance of naproxen-PVP K25 solid dispersions. J Pharm Sci 102 (2013), 1249–1267.
90. 90 Keen, J., Martin, C., Machado, A., Sandhu, H., McGinity, J., DiNunzio, J., Investigation of process temperature and screw speed on properties of a pharmaceutical solid dispersion using corotating and counter-rotating twin-screw extruders. J Pharm Pharmacol 66 (2014), 204–217.
91. 91 Dengale, S., Hussen, S., Krishna, B., Musmade, P., Shenoy, G., Bhat, K., Fabrication, solid-state characterization and bioavailability assessment of stable amorphous phases of ritonavir with quercetin. Eur J Pharm Biopharm 89 (2015), 329–338.
92. 92 Shen, T., Sun, B., Xin, S., Effects of metalloids on the thermal stability and glass forming ability of bulk ferromagnetic metallic glasses. J Alloys Compd 631 (2015), 60–66.
93. 93 Petrovic, A., Dynamic fragility and reduced glass transition temperature as a pair of parameters for estimating glass forming ability. J Non-Cryst Solids 417-418 (2015), 1–9.
94. 94 Kawakami, K., Harada, T., Yoshihashi, Y., Yonemochi, E., Terada, K., Moriyama, H., Correlation between glass-forming ability and fragility of pharmaceutical compounds. J Phys Chem B 119 (2015), 4873–4880.
95. 95 Pina, M., Pinto, J., Sousa, J., Craig, D., Zhao, M., Generation of hydrate form of paroxetine HCL from the amorphous state: an evaluation of thermodynamics and experimental predictive approaches. Int J Pharm 481 (2015), 114–124.
96. 96 Milne, M., Liebenberg, W., Aucamp, M., The stabilization of amorphous zopiclone in an amorphous solid dispersion. AAPS PharmSciTech 16 (2015), 1190–1202.
97. g temperature region. J Phys Chem B 115 (2011), 11375–11381.
98. 98 Janssens, S., Mooter, G., Review: physical chemistry of solid dispersions. J Pharm Pharmacol 61 (2009), 1571–1586.
99. 99 Surwase, S., Itkonen, L., Aaltonen, J., et al. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension. Eur J Pharm Biopharm 96 (2015), 32–43.
100. 100 Tian, Y., Jones, D., Andrews, G., An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems. Mol Pharm 12 (2015), 1180–1192.
101. 101 Laitinen, R., Lobmann, K., Strachan, C., Grohganz, H., Rades, T., Emerging trends in the stabilization of amorphous drugs. Int J Pharm 453 (2013), 65–79.
102. 102 Luk, E., Sandoval, A., Cova, A., Muller, A., Anti-plasticization of cassava starch by complexing fatty acids. Carbohydr Res 98 (2013), 659–664.
103. 103 Penzel, E., Rieger, J., Schneider, H., The glass transition temperature of random copolymers: 1. Experimental data and the Gordon-Taylor equation. Polymer 38 (1997), 325–327.
104. 104 Wlodarski, K., Sawicki, W., Kozrya, A., Tajber, L., Physical stability of solid dispersions with respect to thermodynamic solubility of tadaafil in PVP-VA. Eur J Pharm Sci 96 (2015), 237–246.
105. 105 Tian, B., Wang, X., Zhang, Y., Zhang, K., Zhang, Y., Tang, X., Theoretical prediction of a phase diagram for solid dispersions. Pharm Res 32 (2015), 840–851.
106. 106 Song, Y., Yang, X., Chen, X., Nie, H., Byrn, S., Lubach, J., Investigation of drug-excipient interaction in lapatinib amorphous solid dispersions using solid-state NMR spectroscopy. Mol Pharm 12 (2015), 857–866.
107. 107 Prudic, A., Lesanik, A., Ji, Y., Sadowski, G., Thermodynamic phase behaviour of indomethacin/PLGA formulation. Eur J Pharm Biopharm 93 (2015), 88–94.
108. 108 Sathigari, S.K., Radhakrishnan, V.K., Davis, V.A., Parsons, D.L., Babu, R.J., Amorphous-state characterization of efavirenz-polymer hot-melt extrusion systems for dissolution enhancement. J Pharm Sci 101 (2012), 3456–3464.
109. 109 Couchman, P., Karasz, F., A classical thermodynamic discussion of the effect of composition on glass transition temperatures. Macromolecules 11 (1978), 117–119.
110. 110 Paudal, A., Van Humbeeck, J, Van den Mooter, G., Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). Mol Pharm 7 (2010), 1133–11148.
111. 111 Crowley, K., Zografi, G., Water vapour absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J Pharm Sci 91 (2002), 2150–2165.
112. 112 Fule, R, Amin, P, Development and evaluation of lafutidine solid dispersion via hot-melt extrusion: INvestigating drug-polymer miscibility with advanced characterization. Asian J Pharm Sci 9 (2014), 92–106.
113. 113 Paudel, A., Worku, Z.A., Meeus, J., Guns, S., Mooter, G., Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process consideration. Int J Pharm 453:1 (2013), 253–284.
114. 114 Khougaz, K., Clas, S.D., Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci 89 (2000), 1325–1334.
115. 115 Meng, F., Trivino, A., Prasad, D., Chauhan, H., Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. Eur J Pharm Sci 71 (2015), 12–24.
116. 116 Miyazaki, T., Aso, Y., Yoshioka, S., Kawanishi, T., Differences in crystallization rate of nifedipine enantiomers in amorphous solid dispersions with HPMC and HPMCP. Int J Pharm 407 (2011), 111–118.
117. 117 Shah, N., Iyer, R., Mail, H., Choi, D., Tian, H., Diodane, R., Improved human bioavailabilty of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilised solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci 102 (2013), 967–981.
118. 118 Maniruzzaman, M., Morgan, D., Mendham, A., Pang, J., Snowden, M., Douroumis, D., Drug-polymer intermolecular interactions in hot-melt extruded solid dispersions. Int J Pharm 443 (2013), 199–208.
119. 119 Yang, Z., Nollenberger, K., Albers, J., Craig, D., Qi, S., Molecular indicators of surface and bulk instability of hot melt extruded amorphous solid dispersions. Pharm Res 32 (2015), 1210–1228.
120. 120 Bhugra, C, Pikal, MJ, Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97 (2008), 1329–1349.
121. 121 Miura, H., Kanebako, M., Shirai, H., Nakao, H., Inagi, T., Terada, K., Stability of amorphous drug 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, in silica mesopores and measurements of its molecular mobility by solid-state 13C NMR spectroscopy. Int J Pharm 410 (2011), 61–67.
122. 122 Schamme, B., Couvrat, N., Malpeli, P., et al. Crystallization kinetics and molecular mobility of an amorphous active pharmaceutical ingredient: a case study with biclotymol. Int J Pharm 490 (2015), 248–257.
123. 123 Urbanova, M., Sturcova, A., Kredatusova, J., Brus, J., Structural insight into the physical stability of amorphous simvastatin dispersed pHPMA: enhanced dynamics and local clustering as evidenced by solid-state NMR and Raman spectroscopy. Int J Pharm 478 (2015), 464–475.
124. 124 Bhardwaj, S., Suryanarayanan, R., Use of dielectric spectroscopy to monitor molecular mobility in glassy and supercooled trahalose. J Phys Chem 116 (2012), 11728–11736.
125. 125 Knapik, J., Wojnarowska, Z., Grzybowska, K., et al. Physical stability of the amorphous anticholesterol agent (ezetimibe): the role of molecular mobility. Mol Pharm 11 (2014), 4280–4290.
126. 126 Mistry, P., Mohapatra, S., Gopinath, T., Vogt, F., Suryanarayanan, R., Role of the strength of drug polymer interactions on the molecular mobility and crystallization inhibition in ketoconazole solid dispersion. Mol Pharm 12 (2015), 3339–3350.
127. 127 Kothari, K., Ragoonanan, V., Suryanarayanan, R., The role of polymer concentration on the molecular mobility and physical stability of nifedipine solid dispersions. Mol Pharm 12 (2015), 1477–1484.
128. 128 Robertis, S., Bonferoni, M., Elviri, L., Sandri, G., Caramella, C., Bettini, R., Advances in oral controlled drug delivery: the role of drug-polymer and interpolymer non-covalent interactions. Expert Opin Drug Deliv 12 (2015), 441–453.
129. 129 Broman, E., Khoo, C., Taylor, L., A comparison of alternative polymer excipients and processing methods for making solid dispersion of poorly water soluble drug. Int J Pharm 222 (2001), 139–151.
130. 130 Ilevbare, G., Liu, H., Edgar, K., Taylor, L., Understanding polymer properties important for crystal growth inhibition - Impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des 12 (2012), 3133–3143.
131. 131 Higashi, K., Hayashi, H., Yamamoto, K., Moribe, K., The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersion on the drug and polymer dissolution rate. Int J Pharm 494 (2015), 9–16.
132. 132 Mohammad, A.M., Alhalaweh, A., Velaga, PS, Hansen solubility parameter as a tool to predict cocrystal formation. Int J Pharm 407 (2011), 63–71.
133. 133 Liu, J., Cao, F., Zhang, C., Ping, Q., Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion. Acta Pharm Sin B 3 (2013), 263–272.
134. 134 van Krevelen, D.W., Nijenhuis, K., Properties of Polymers: Their Correlation With Chemical Structures, Their Numerical Estimations and Prediction From Additive Group Contribution Method. Chapter 7. 4th ed., 2009, Elsevier, Amsterdam.
135. 135 Taylor, L., Li, T., Marsac, P., Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 26 (2009), 139–151.
136. 136 Barton, M.F.A, Solubility parameters. Chem Rev 75 (1975), 731–753.
137. 137 Zhao, Y., Inbar, P., Chokshi, H., Malick, W., Choi, D., Prediction of the thermal phase diagram of amorphous solid dispersion by Flory-Huggins theory. J Pharm Sci 100 (2011), 3196–3207.
138. 138 Verma, S., Rudraraju, V., A systematic approach to design and prepare solid dispersions of poorly water-soluble drug. AAPS PharmSciTech 15 (2014), 641–657.
139. 139 Thakral, S, Thakral, NK, Prediction of drug-polymer miscibility through the use of solubility parameter based Flory-Huggins interaction parameter and the experimental validation: PEG as model polymer. J Pharm Sci 102 (2013), 2254–2263.
140. 140 Tian, Y., Booth, J., Meehan, E., Jones, D., Li, S., Andrews, G., Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersion. Mol Pharm 10 (2012), 236–248.
141. 141 Djuris, J, Nikolakakis, I, Ibric, S, Djuric, Z, Kachrimanis, K, Preparation of carbamazepine-soluplus solid dispersios by hot-melt extrusions, and prediction of drug-polymer miscibility by thermodynamic model fitting. Eur J Pharm Biopharm 84 (2013), 228–237.
142. 142 Amharar, Y., Curtin, V., Gallagher, K., Healy, A., Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation. Int J Pharm 472 (2014), 241–247.
143. 143 Ahmad, S., Johnston, B., Mackay, S., et al. In silico modelling of drug-polymer interactions for pharmaceutical formulations. J R Soc Interface 7 (2010), S423–S433.
144. 144 Ouyang, D., Investigating the molecular structure of solid dispersions by the simulated annealing method. Chem Phys Lett 554 (2012), 177–184.
145. 145 Persson, L., Porter, C., Charman, W., Bergstrom, C., Computational prediction of drug solubility in lipid based formulation excipients. Pharm Res 30 (2013), 3225–3237.
146. 146 Gupta, J., Nunes, C., Vyas, S., Jonnalagadda, S., Prediction of solubility parameters and miscibility of pharmaceutical compounds by molecular dynamics simulations. J Phys Chem B 115 (2011), 2014–2023.
147. 147 Maniruzzaman, M, Pang, J, Morgan, DJ, Douroumis, D, Molecular modeling as a predictive tool for the development of solid dispersions. Mol Pharm 12 (2015), 1040–1049.
148. 148 Svajani, K., Gajjar, A., Savjani, J., Drug solubility: importance and enhancement techniques. ISRN Pharm 2012 (2012), 1–10.
149. 149 Yoo, S., Krill, S., Wang, Z., Telang, C., Miscibility/stability considerations in binary solid dispersion system composed of functional excipients towards the design of multi-component amorphous system. J Pharm Sci 98 (2009), 4711–4723.
150. 150 Wanare, R., Enhancement of dissolution rate of poorly water soluble drug by solid dispersion technique. Res J Pharm Biol Chem 4 (2013), 686–707.
151. 151 Nabarawi, M., Miligi, M., Khalil, I., Optimization of class II BCS drug using solid dispersion technique. Int J Pharm Pharm Sci 4 (2012), 554–571.
152. 152 Das, S., Roy, S., Kalimuthu, Y., Khanam, J., Nanda, A., Solid dispersion: an approach to enhance the bioavailability of poorly water soluble drugs. Int J Pharmacol Pharm 1 (2012), 37–46.
153. 153 Sekiguchi, K., Obi, N., Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 9 (1961), 866–872.
154. 154 Ghebremeskel, N., Vemavarpu, C., Lodaya, M., Use of surfactant as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Pharm Res 23 (2006), 1928–1936.
155. 155 Munjal, M., Stodghill, P., Elsohly, A., Repka, A., Polymeric systems for amorphous delta 9-tetrhydrocannabinol produced by a hot-melt method. Part I: chemical and thermal stability during processing. J Pharm Sci 95 (2006), 2473–2485.
156. 156 Qi, S., Belton, P., Nollenberger, K., Clayden, N., Reading, M., Craig, D., Characterization and prediction of phase separation in hot-melt extruded solid dispersions: a thermal, microscopic and NMR relaxometry study. Pharm Res 27 (2010), 1869–1883.
157. 157 Save, T., Venkitachalam, P., Studies on solid dispersion of nifedipine. Drug Dev Ind Pharm 18 (1992), 1663–1679.
158. 158 Patil, H., Tiwari, R., Repka, M., Hot-melt extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech, 2015 http://doi/dx/10.1208/s12249-015-0360-7.
159. 159 Repka, M., Battu, S., Upadhye, S., et al. Pharmaceutical application of hot-melt extrusion: part II. Drug Dev Ind Pharm 33 (2007), 1043–1057.
160. 160 Sharma, A., Jain, C., Solid dispersion: a promising technique to enhance solubility of poorly water soluble drug. Int J Drug Deliv 3 (2011), 149–179.
161. 161 Serajuddin, A., Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent breakthroughs. J Pharm Sci 88 (1999), 1058–1066.
162. 162 Vehring, R., Pharmaceutical particle engineering via spray drying. Pharm Res 25 (2008), 999–1022.
163. 163 Giovagnoli, S, Palazzo, F, Di Michele, A, Schoubben, A, Blasi, P, Ricci, M, The influence of feedstock and process variables on the encapsulation of drug-suspensions by spray drying in fast drying regime: The case of novel antitubercular drug-palladium complex containing polymeric microparticles. J Pharm Sci 103 (2014), 1255–1268.
164. 164 Araujo, R., Teixeira, C., Freitas, L., The preparation of ternary solid dispersions of an herbal drug via spray drying of liquid feed. Dry Technol 28 (2010), 412–421.
165. 165 Corrigan, O., Thermal analysis of spray dried products. Thermochimica Acta 248 (1995), 245–258.
166. 166 Mahlin, D., Ponnambalam, S., Heidarian, H., Bergstrom, M., Towards in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development. Mol Pharm 8 (2011), 498–506.
167. 167 Baird, A., Santiago, Q., Rinaldi, C., Taylor, S., Role of viscosity in influencing the glass forming ability of organic molecules from the undercooled melt state. Pharm Res 1 (2012), 271–284.
168. 168 Solluhub, K., Cal, K., Spray drying technique. II. Current application in pharmaceutical technology. J Pharm Sci 99 (2010), 587–597.
169. 169 Srinarong, P., de Waard, H., Frijlink, W., Hinrichs, L., Improved dissolution behaviour of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations. Expert Opin Drug Deliv, 8, 2011, 1020.
170. 170 Thakkar, F., Soni, T., Gohel, M., Gandhi, T., Supercritical fluid technology: a promising approach to enhance the drug solubility. J Pharm Sci Res 1 (2009), 1–14.
171. 171 Sunkara, G., Kompella, U., Drug delivery application of supercritical fluid technology. Drug Deliv Tech 58 (2002), 615–619.
172. 172 Subramaniam, B., Rajewski, A., Snavely, K., Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 86 (1997), 885–890.
173. 173 Wu, K., Li, J., Wang, W., Winstead, D., Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J Pharm Sci 98 (2009), 2422–2431.
174. 174 Jun, S., Kim, M., Jo, G., et al. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. J Pharm Pharmacol 57 (2005), 1529–1537.
175. 175 Kim, M., Jin, S., Kim, J., et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69 (2008), 454–465.
176. 176 Corrigan, O., Crean, A., Comparative physicochemical properties of hydrocortisone-PVP composites prepared using supercritical carbon dioxide by the GAS anti-solvent recrystallization process, by coprecipitation and spray drying. Int J Pharm 245 (2002), 75–82.
177. 177 Lee, S., Nam, K., Kim, M., et al. Preparation and characterization of solid dispersion of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch Pharm Res 2 (2005), 866–874.
178. 178 Engers, D., Teng, J., Jimenez, J., et al. A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. J Pharm Sci 99 (2010), 3901–3922.
179. 179 Moes, J., Koolen, S., Huitema, A., Schellen, J., Beijnan, J., Nuijen, B., Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur J Pharm Biopharm 83 (2013), 87–94.
180. 180 Zhao, Y., Xin, T., Ye, T., Yang, X., Pan, W., Solid dispersion in the development of a nimodipine delayed release tablet formulation. Asian J Pharm Sci 9 (2014), 35–41.
181. 181 Al-Obaidi, H., Lawrence, M., Al-Saden, N., Ke, P., Investigation of griseofulvin and hydroxypropylmethyl cellulose acetate succinate miscibility in ball milled solid dispersions. Int J Pharm Sci 443 (2013), 95–102.
182. 182 Chauhan, A., Chauhan, P., Powder XRD technique and its application in science and technology. J Anal Bioanal Tech 5 (2014), 1–5.
183. 183 Zhu, Q., Toth, S., Simpson, G., Hsu, H., Taylor, L., Harris, M., Crystallization and dissolution behaviour of naproxen/polyethylene glycol solid dispersions. J Phys Chem 117 (2013), 1494–1500.
184. 184 Botker, J., Karmwar, P., Strachan, C., et al. Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions. Int J Pharm 417 (2011), 112–119.
185. 185 Nollenberger, K., Gryczke, A., Meier, C., Dressman, J., Schmidt, M., Bruhne, S., Pair distribution function X-ray analysis explains dissolution characteristics of felodipine melt extrusion products. J Pharm Sci 98 (2009), 1476–1486.
186. 186 Baird, J., Taylor, L., Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev 64 (2012), 396–421.
187. 187 Mahajan, D., Raut, D., Sakharkar, D., Bodke, P., Determination of traces of amorphous carvedilol content in carvedilol drug substance and drug product using modulated differential scanning calorimetry. Der Pharm Lett 3 (2011), 1–12.
188. 188 Ford, J., Mann, T., Fast-scan DSC and its role in pharmaceutical physical form characterization and selection. Adv Drug Deliv Rev 64 (2012), 422–430.
189. 189 Jones, D., Tian, Y., Abu-Diak, O., Andrews, G., Pharmaceutical applications of dynamic mechanical thermal analysis. Adv Drug Deliv Rev 64 (2012), 440–448.
190. 190 Zhang, J., Bunker, M., Chen, X., Parker, A., Patel, N., Roberts, C., Nanoscale thermal analysis of pharmaceutical solid dispersions. Int J Pharm 380 (2009), 170–173.
191. 191 Foster, A., Hempenstall, J., Rades, T., Characterization of glass solution of poorly water soluble drugs by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol 53 (2001), 303–315.
192. 192 Ewing, A., Clarke, G., Kazarian, S., Stability of indomethacin with relevance to the release from amorphous solid dispersions studied with ATR-FTIR spectroscopic imaging. Eur J Pharm Sci 60 (2014), 64–71.
193. 193 Loh, G., Tan, Y., Peh, K., Hydrophilic polymer solubilization on norfloxacin solubility in preparation of solid dispersion. Powder Technol 256 (2014), 462–469.
194. 194 Ayenew, Z., Paudel, A., Mooter, G., Can compression induce demixing in amorphous solid dispersion? A case study of naproxen-PVP K25. Eur J Pharm Biopharm 81 (2012), 207–213.
195. 195 Bugay, D., Characterization of the solid state: spectroscopic techniques. Adv Drug Deliv Rev 48 (2001), 43–65.
196. 196 Furuyama, N., Hasegawa, S., Hamaura, T., et al. Evaluation of solid dispersions on a molecular level by the Raman mapping technique. Int J Pharm 361 (2008), 12–18.
197. 197 Sinclair, W., Leane, M., Clarke, G., Dennis, A., Tobyn, M., Timmins, P., Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform Raman spectroscopy. J Pharm Sci 100 (2011), 4687–4699.
198. 198 Kanaujia, P., Lau, G., Widjaja, E., et al. Investigating the effect of moisture protection on solid-state stability and dissolution of fenofibrate and ketoconazole solid dispersions using PXRD, HSDSC and Raman microscopy. Drug Dev Ind Pharm 37 (2011), 1026–1035.
199. 199 Chen, Y, Liu, C, Chen, Z, Su, C, Hageman, M, Hussain, M, Haskell, R, Stefanski, K, Qian, F, Drug-polymer-water interaction and its implication to the dissolution performance of amorphous solid dispersions. Mol Pharm 12 (2015), 576–589.
200. 200 Puncochova, K., Heng, J., Beranek, J., Stepanek, F., Investigation of drug-polymer interaction in solid dispersions by vapour sorption methods. Int J Pharm 469 (2014), 159–167.
201. 201 Ticehurst, M., Basford, P., Dallman, C., et al. Characterization of the influence of micronization on the crystallinity and physical stability of revatropate hydrobromide. Int J Pharm 193 (2000), 247–259.
202. 202 Enose, A., Dasan, P., Sivaramakrishnan, H., Shah, S., Formulation and characterization of solid dispersion prepared by hot melt mixing: a fast screening approach for polymer selection. J Pharm 2014 (2014), 1–13.
203. 203 Lane, R., Buckton, G., The novel combination of dynamic vapour sorption gravimetric analysis and near infra-red spectroscopy as a hyphenated technique. Int J Pharm 207 (2000), 49–56.
204. 204 Paudel, A., Geppi, M., Mooter, G., Structural and dynamic properties of amorphous solid dispersions: the role of solid-state nuclear magnetic resonance spectroscopy and relaxometry. J Pharm Sci 103 (2014), 2635–2662.
205. 205 Yuan, X., Sperger, D., Munson, E., Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-stste NMR spectroscopy. Mol Pharm 11 (2014), 329–337.
206. 206 Litvinov, V., Guns, S., Adriaensens, P., et al. Solid state solubility of miconazole in poly[(ethylene glycol)-g-vinylalcohol] using hot-melt extrusion. Mol Pharm 9 (2012), 2924–2932.
207. 207 Ito, A., Watanabe, T., Yada, S., et al. Prediction of recrystallization behaviour of troglitazone/polyvinylpyrrolidone solid dispersion by solid-state NMR. Int J Pharm 383 (2010), 18–23.
208. 208 Dahlberg, C., Fureby, A., Schuleit, M., Furo, I., Relationships between solid dispersion preparation process, particle size and drug release—an NMR and NMR micro imaging study. Eur J Pharm Biopharm 76 (2010), 311–319.
209. 209 Ho, R., Jery, Y., A review of inverse gas chromatography and its development as a tool to characterize anisotropic surface properties of pharmaceutical solids. KONA Powder Part J 30 (2013), 164–180.
210. 210 Buckton, G., Gill, H., The importance of surface energetics of powders for drug delivery and the establishment of inverse gas chromatography. Adv Drug Deliv Rev 59 (2007), 1474–1479.
211. 211 Sun, Y., Zhu, L., Wu, T., Cai, T., Gunn, E., Yu, L., Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives. AAPS J 14 (2012), 380–388.
212. 212 Hasegawa, S., Ke, P., Buckton, G., Determination of the structural relaxation at the surface of amorphous solid dispersion using inverse gas chromatography. J Pharm Sci 98 (2009), 2133–2139.
213. 213 Miyanishi, H., Nemoto, T., Mizuno, M., et al. Evaluation of crystallization behaviour on the surface of nifedipine solid dispersion powder using inverse gas chromatography. Pharm Res 30 (2013), 502–511.
214. 214 Qian, F., Wang, J., Hartley, R., et al. Solution behaviour of PVP-PA and HPMC-AS based amorphous solid dispersion and their bioavailability implications. Pharm Res 29 (2012), 2765–2776.
215. 215 Yan, H., Chris, H., Amorphous solid dispersions: utilization and challenges in drug discovery and development. J Pharm Sci 104 (2015), 3237–3258.
216. 216 Raina, S., Alonzo, D., Zhang, G., Gao, Y., Taylor, L., Impact of polymers on crystallization and phase transition kinetics of amorphous nifedipine during dissolution in aqueous media. Mol Pharm 11 (2014), 3565–3576.
217. 217 Gauzman, H., Tawa, M., Zhang, Z., et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 26 (2009), 855–864.